http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
지각된 위험과 지각된 편익이 구매의도에 미치는 영향 -의료관광사업 중국잠재수요자 중심으로
이지은 ( Ji Eun Lee ),추옥걸 ( Yu Jie Zou ) 한국병원경영학회 2015 병원경영학회지 Vol.20 No.1
China has a growing number of medical tourists to visit South Korea every year, with economic growth, and thus Korea``s medical tourism is growing countries in the new growth engine industries and attracting attention. In this study, this time looking at the risks and benefits of medical tourism potential factors consumers feel the Chinese people for South Korea medical tourism, economic, based on existing research, functional, temporal, social, and psychological setting factors, risks and benefits conducted a study of the relationship between the purchase of your help. Risk factors identified through this study, we investigate expanding the overseas medical tourism market to visit Korea by managing the benefits and know the strategic implications that can achieve customer satisfaction by the service convenient for Chinese tourists.
전이성 신세포암에서 Everolimus 사용 후 유발된 당뇨병성 케톤산증 1예
김이경 ( Lee Kyung Kim ),안창호 ( Chang Ho Ahn ),이지은 ( Jie Eun Lee ),정찬현 ( Chan Hyeon Jung ),구보경 ( Bo Kyung Koo ),문민경 ( Min Kyong Moon ) 대한내과학회 2014 대한내과학회지 Vol.86 No.6
신세포암, 유방암, 췌장의 신경내분비종 등의 치료에 사용이 증가하고 있는 mTOR 억제제인 everolimus의 치료 시고혈당, 고지질혈증 등의 대사 이상이 발생할 수 있음이 알려져 있으나 당뇨병성 케톤산증의 발생은 보고된 바 없다. 저자들은 전이성 신세포암에서 everolimus 투여 후 발생한 당뇨병성 케톤산증 1예를 경험하였기에 문헌고찰과 함께 보고하는 바이다. Everolimus, an inhibitor of the mammalian target of the rapamycin (mTOR) pathway, is widely used as an immunosuppressant for the prevention of organ rejection following transplant and to treat metastatic clear-cell type renal cell carcinoma (RCC), breast cancer, and pancreatic neuroendocrine tumors. Everolimus commonly induces metabolic abnormalities such as hyperglycemia, hypercholesterolemia, and hypertriglyceridemia due to concomitant increases in blood glucose levels via the induction of insulin resistance and a decrease in β cell function, which both lead to insulin deficiency. Although abnormal blood glucose levels are observed in more than 50% of patients treated with Everolimus, hyperglycemia exceeding 500 mg/dL is not common and there have been no reports of Everolimus-induced acute hyperglycemic crisis conditions. Here, a novel case of Everolimus-associated diabetic ketoacidosis (DKA) in a patient with RCC is reported. (Korean J Med 2014;86:761-765)